The Technical AnalystExchange: PNK Industry: Biotechnology
TetraLogic Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0001
America/New_York / 13 des 2023 @ 15:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.459 mill |
| EPS: | -0.0100 |
| P/E: | -0.0100 |
| Earnings Date: | May 17, 2024 |
| SharesOutstanding: | 4 587.20 mill |
| Avg Daily Volume: | 0 mill |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/15 | 3/15 | 4/15 | 1/16 | 2/16 | 3/16 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0100 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0001 - 0.0001 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2016-11-14 | Highbridge Capital Management Llc | Buy | 0 | |
| 2016-11-14 | Whitebox Advisors Llc | Buy | 3 018 260 | Preferred Stock |
| 2016-11-14 | Whitebox Advisors Llc | Sell | 0 | 8% Senior Convertible Notes due 2019 |
| 2016-11-14 | Whitebox Advisors Llc | Buy | 0 | 8% Senior Convertible Notes due 2024 |
| 2016-11-14 | Hudson Bay Capital Management Lp | Buy | 279 367 | Preferred Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 89 transactions |
| Buy: 6 009 229 | Sell: 2 506 005 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0001 (0.00% ) |
| Volume | 0.0001 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TLOG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TLOG
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.